Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells

BACKGROUND: Pancreatic cancer (PC) is the fourth most common cause of cancer death. Combination therapies with classical chemotherapeutic agents improved treatment of advanced PC at the cost of a relevant toxicity, but the 5-year survival rate remains below 5%. Consequently, new therapeutic options...

Full description

Saved in:
Bibliographic Details
Published in:J Exp Clin Cancer Res
Main Authors: Veschi, Serena, De Lellis, Laura, Florio, Rosalba, Lanuti, Paola, Massucci, Alberto, Tinari, Nicola, De Tursi, Michele, di Sebastiano, Pierluigi, Marchisio, Marco, Natoli, Clara, Cama, Alessandro
Format: Artigo
Language:Inglês
Published: BioMed Central 2018
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6151049/
https://ncbi.nlm.nih.gov/pubmed/30241558
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-018-0904-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items